Cyclin-dependent kinase 14 (CDK14)

Cyclin-dependent kinase 14 (CDK14) is a member of the cyclin-dependent kinase family, classified within the TAIRE subfamily, and functions as a serine/threonine protein kinase[1][5]. It is primarily involved in regulating cell cycle progression and cell proliferation, integrating signals from pathways such as TGF-β and Wnt/β-catenin to control cellular responses[2][3]. CDK14 is overexpressed in various cancer types, including ovarian cancer, where it serves as a biomarker for paclitaxel resistance and is correlated with poor patient prognosis. Knockdown of CDK14 in cancer models reduces cell proliferation and enhances chemosensitivity, highlighting its potential as a therapeutic target for overcoming drug resistance. CDK14 interacts with regulatory cyclins for its activation and displays substrate specificity commonly seen in the CDK family. The enzyme is encoded by the CDK14 gene located on chromosome 7q21.13 in humans[1][9].

Other names

cell division protein kinase 14PFTAIRE protein kinase 1PFTAIRE1PFTK1

Inhibition of CDK14 can reduce cell proliferation and induce apoptosis in cancer cells; modulation of chemosensitivity, particularly to paclitaxel, in ovarian cancer